Breakthrough in Tablet Manufacturing with Jungbunzlauer's TCC
Jungbunzlauer's TCC TB: A Game-Changer in Tablet Production
Research has unveiled the remarkable capabilities of Jungbunzlauer's tricalcium citrate (TCC TB), a substance that promises to revolutionize tablet manufacturing in the pharmaceutical and nutraceutical sectors. As industry demands for high-quality ingredients continue, Jungbunzlauer is at the forefront, delivering pivotal advancements that ensure efficient production processes.
Collaboration Highlights Innovation
In collaboration with Professor Karl Wagner from the University of Bonn, this research demonstrates the exceptional properties of TCC TB in direct compression processes. "This partnership highlights our dedication to innovative solutions and product excellence," stated Markus Gerhart, Senior Director at Jungbunzlauer. His words underline the importance of thorough scientific inquiry and quality assurance in the development of this essential excipient.
The Advantages of Direct Compression
Direct compression is a favored method in the industry due to its ability to handle sensitive ingredients effectively. However, it requires excipients that exhibit superior flow and compactibility. The insights from this new research confirm that TCC TB outperforms in these areas, providing excellent flowability and robust tablet strength, even when subjected to minimal compression force.
Exceptional Quality and Safety Standards
Jungbunzlauer's TCC TB does not just excel in manufacturing; it also meets rigorous safety standards. Produced through the complete neutralization of citric acid with a high purity calcium source, TCC TB is certified vegan and free from allergens and GMOs. It adheres to USP, FCC, and EU quality standards, ensuring that it is a safe choice for various applications.
Impact on Complex Formulations
The study's findings reveal that TCC TB is particularly efficient for complex formulations such as minitablets, moisture-sensitive active pharmaceutical ingredients (APIs), and botanical compounds. Its rapid disintegration capabilities allow for the efficient creation of tablets that can meet specific market needs.
Future Presentations and Engagement
The groundbreaking findings of this research will be showcased at an upcoming industry event, where professionals can engage with Jungbunzlauer. Industry experts and attendees will have the opportunity to discuss the performance data of TCC TB and explore its potential for their own formulation challenges.
About Jungbunzlauer
With a legacy of over 150 years, Jungbunzlauer has established itself as a leader in producing high-quality, sustainable ingredients sourced from nature. The company serves a variety of industries, including food and beverage, health, and personal care. Jungbunzlauer prides itself on innovation, offering a diverse range of products that enhance everyday life while addressing evolving consumer needs.
Headquartered in Basel, Switzerland, Jungbunzlauer operates state-of-the-art facilities, including extensive fermentation processes throughout Europe and North America. Their commitment to sustainability and quality is evident in their operations, which support a healthier future worldwide.
Frequently Asked Questions
What is Jungbunzlauer's TCC TB?
TCC TB is a tricalcium citrate product used as an excipient for tablet manufacturing, known for its excellent flowability and tablet strength.
How does TCC TB improve tablet manufacturing?
TCC TB enhances the direct compression process by providing superior flow properties and robust tablet formation, helping to produce high-quality tablets efficiently.
What standards does TCC TB meet?
TCC TB is certified vegan, allergen-free, and adheres to USP, FCC, and EU standards, ensuring safety and quality in its applications.
Where can I learn more about Jungbunzlauer?
Visit Jungbunzlauer's official website for more information about their products and commitment to sustainability in ingredient production.
Will there be any events showcasing TCC TB?
Yes, the findings on TCC TB will be presented at CPHI Global, where industry professionals can engage directly with Jungbunzlauer representatives.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.